Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2019-12-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于收到《企业境外投资证书》和《项目备案通知书》公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 福安药业（集团）股份有限公司 regarding the receipt of an "Enterprise Overseas Investment Certificate" and a "Project Filing Notice." It details the company's board resolutions about acquiring a 51% stake in Red Realty LLC through a subsidiary, the establishment of a secondary subsidiary in the US, and the official approval and registration of this overseas investment project. The document does not contain financial statements or detailed financial performance data but rather regulatory approvals and project progress updates related to overseas investment. It is not a full financial report, earnings release, or management discussion. The content fits best with a Regulatory Filing (RNS) as it is a formal announcement of regulatory approvals and project status without substantive financial data or report content.
2019-12-24 Chinese
关于收到枸橼酸托瑞米芬片一致性评价受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (737 characters) from a company about receiving a regulatory acceptance notice from the National Medical Products Administration regarding a drug consistency evaluation. It is an official announcement of a regulatory event related to product approval, not a financial report, management change, or shareholder meeting material. It does not contain financial data or detailed report content. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2019-12-16 Chinese
关于美国二级子公司完成注册登记的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (672 characters) about the completion of registration of a US subsidiary by the company. It includes details about the registration and references a prior announcement. There is no financial data, no report attached or published, and no detailed financial or management discussion. It is an official announcement related to corporate structure and business expansion but does not fit categories like Annual Report, Interim Report, or Capital Update. It is not a Board/Management change announcement either, as it concerns subsidiary registration. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2019-12-02 Chinese
关于高级管理人员股份减持计划的预披露公告
Director's Dealing Classification · 100% confidence The document is a public announcement regarding a share reduction plan by senior management personnel of the company 福安药业 (Fuan Pharmaceutical). It details the shareholders involved, the number of shares to be reduced, the method of reduction, the timing, and legal compliance. The content focuses on insider share transactions by company executives and does not contain financial statements, earnings data, or regulatory certifications. It is not an annual or interim report, nor a call transcript or governance report. The key aspect is the disclosure of personal share transactions by directors and senior management, which fits the definition of Director's Dealing filings.
2019-11-27 Chinese
关于控股股东协议转让部分公司股份完成过户登记的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a share transfer agreement between the controlling shareholder and another investor, detailing the number of shares transferred, the percentage of total shares, and confirming that the controlling shareholder and actual controller have not changed. It includes references to regulatory compliance and the issuance of a securities transfer confirmation certificate. The content focuses on changes in significant share ownership levels and does not contain financial statements or detailed financial performance data. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and it is not a report or a certification, so it is not classified as a regulatory filing or report publication announcement.
2019-11-25 Chinese
关于公司第一期员工持股计划锁定期满暨减持计划的预披露公告
Transaction in Own Shares Classification · 95% confidence The document is a pre-disclosure announcement regarding the expiration of the lock-up period and the planned reduction of shares held under the company's first employee stock ownership plan. It details the background of the employee stock plan, the shareholding situation, the lock-up period expiration, and the intended share reduction plan including timing, quantity, and method. The document is an announcement about a share reduction plan related to an employee stock ownership plan, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on shareholding and reduction plans. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buyback or sale of its own shares, including employee stock plan share reductions.
2019-11-20 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.